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Abstract
Background: During blood meal, the female mosquito injects saliva able to elicit an immune response in the
vertebrate. This immune response has been proven to reflect the intensity of exposure to mosquito bites and risk
of infection for vector transmitted pathogens such as malaria. The peptide gSG6-P1 of An. gambiae saliva has
been demonstrated to be antigenic and highly specific to Anopheles as a genus. However, the applicability of
gSG6-P1 to measure exposure to different Anopheles species endemic in the Americas has yet to be evaluated.
The purpose of this pilot study was to test whether human participants living in American countries present
antibodies able to recognize the gSG6-P1, and whether these antibodies are useful as a proxy for mosquito bite
exposure and malaria risk.
Methods: We tested human serum samples from Colombia, Chile, and the United States for the presence of IgG
antibodies against gSG6-P1 by ELISA. Antibody concentrations were expressed as delta optical density (ΔOD) of
each sera tested in duplicates. The difference in the antibody concentrations between groups was tested using
the nonparametric Mann Whitney test (independent groups) and the nonparametric Wilcoxon matched-pairs
signed rank test (dependent groups). All differences were considered significant with a P < 0.05.
Results: We found that the concentration of gSG6-P1 antibodies was significantly correlated with malaria
infection status and mosquito bite exposure history. People with clinical malaria presented significantly higher
concentrations of IgG anti-gSG6-P1 antibodies than healthy controls. Additionally, a significant raise in antibody
concentrations was observed in subjects returning from malaria endemic areas.
Conclusion: Our data shows that gSG6-P1 is a suitable candidate for the evaluation of exposure to Anopheles
mosquito bites, risk of malaria transmission, and effectiveness of protection measures against mosquito bites in
the Americas.
Background
Globally, an estimated 3.3 billion people are at risk of
being infected with malaria [1, 2]. Although the majority
of cases and deaths occur in Africa, approximately 170
million people in the Americas live at risk of malaria
infection, with 74 % of cases caused by Plasmodium vivax
and 25 % by P. falciparum [3, 4]. Malaria is transmitted to
humans when the infective sporozoites, located in salivary
glands, are injected into the human skin through the bite
of a female Anopheles mosquito. These sporozoites are
submerged in mosquito saliva [5] that is used by the mos-
quito to facilitate blood uptake. Mosquito saliva contains
physiologically active components able to counteract
blood coagulation, active complement, and the response
to hinder the bite injury. Interestingly, some of these saliv-
ary components can also elicit and modify immune
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responses in the vertebrate host and can therefore modify
the outcome of vector-transmitted diseases [6, 7].
The gold standard to measure the intensity of malaria
transmission is the entomological inoculation rate
(EIR), which is defined as the number of infectious
Anopheles bites per person in a given time [8]. EIR
measurement is highly dependent on the density of
human-biting Anopheles [9]. The latter is estimated by
trapping methods such as human-landing catches
(HLCs) of adult mosquitoes. However, the technique of
HLC poses ethical concerns as the human “bait” could be
exposed to transmission of malaria and other mosquito-
borne diseases. In addition, this trapping technique is only
applicable to human adults. It is difficult to extrapolate
HLC results to children or to pregnant woman that are
the most vulnerable to malaria [10]. As an alternative,
catching traps such as the CDC light trap, CDC light
trap associated with CO2 or the Mbitrap have been de-
veloped [11]. However, studies have shown that these
alternative methods have several limitations, like prefer-
entially capturing mosquitoes with higher sporozoite
rate and consequently overestimating EIR [12] and can
not replace HLC [13]. Therefore, new tools able to
evaluate vector–host contact as well as the changes of
this contact over time are needed to monitor both
population and individual exposure and disease risk.
Previous works have shown that the immune response
against mosquito salivary proteins, specially IgG anti-
bodies, can reflect the intensity of exposure to mosquito
bites as well as the risk of infection for vector-borne path-
ogens [14–16]. The serological evaluation of this immune
response and its association with the exposure to malaria
vectors is receiving increasing attention, especially regard-
ing the major malaria vectors in Africa and India, An.
gambiae sensu lato and An. stephensi, respectively. Tran-
scriptome analysis of the salivary glands of An. gambiae,
identified a protein named An. gambiae salivary gland
protein 6 (gSG6), a member of the SG protein family
known to be exclusively expressed in the adult Anopheles
female [17]. Most of the SG proteins seem to be very well
conserved among Old World species, An. gambiae, An.
arabiensis, and An. funestus. However, clustal alignment
of gSG6 showed similarities with the New World Anoph-
eles species, An. quadrimaculatus and An. freeborni [18,
19]. The peptide gSG6 is restricted to the Anopheles genus
based on substantial previous research, which has also
demonstrated that specific IgG response to gSG6-P1 could
serve as a biomarker for exposure to malaria vectors [2,
17, 19–25]. Moreover, the use of the gSG6-P1 salivary
peptide has enabled the collection of relevant data on the
efficacy of long lasting insecticide treated nets (LLIN) over
time [26] and to compare the effectiveness of individual
protection tools such as spray bombs and mosquito coils
to LLINs [27].
The development of accurate and sensitive tools to
identify variations in vector exposure and malaria risk is
important to assess the effectiveness of control efforts.
So far, the relevance of antibody response against gSG6-
P1 has only been evaluated in subjects exposed to bites
of Anopheles species in the Old World. The purpose of
this study was to evaluate whether gSG6-P1 is a suitable
biomarker for exposure to bites of American species of
Anopheles, serving as an indicator of the efficacy of indi-
vidual/collective malaria vector control tools and a proxy
for Plasmodium transmission risk in the New World.
Methods
Ethics statement
Universidad de Pamplona, Los Patios Hospital in Norte de
Santander-Colombia, approved this study. Additionally, an
IRB approval from University of North Carolina at Chapel
Hill was granted for the previously described double-blind
RCT examining effects of permethrin-treated uniforms on
the incidence of tick bites in North Carolina outdoor
workers. The Military Hospital and the Chilean Army
Health Command in Santiago, Chile, granted the approval
for the inclusion of Chilean military personnel. Written
consent was obtained from each volunteer.
Study participants
Chile
A sample of Chilean soldiers participating for a period
of 6 months in the United Nations Stabilization Mission
in Haiti (MINUSTAH) in 2011 were included in the
present study (n = 45) (Table 1). They were part of a sur-
veillance project of the Department of Preventive Medi-
cine of the Chilean Military to evaluate the risk of
vector-borne disease for peace troops working in Haiti.
Samples were obtained from troops that were stationed
Table 1 Sample description








Colombia Healthy subjects Before traveling 26
After traveling 26 An. albimanus
An. darlingi
An. punctimacula
Febrile patients Malaria (+) 7
Malaria (−) 35
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in Port-au-Prince and responsible for road and bridge
building. Daily activities included exposure to swamps,
rivers, and flooded roads, as well as diurnal and noctur-
nal patrolling and convoy security duties in different
rural sites. All soldiers received training to avoid mos-
quito exposure before departure. In Haiti, measures
against vector-borne infections included personal use of
skin repellent containing 34 % DEET (Ultrathon™, 3M,
St. Paul, MN, USA), impregnation of occupational
clothes with a permethrin-based repellent, weekly oral
dose of 300 mg of chloroquine (base), sleeping in
container-type facilities with air-conditioning, and in-
door residual spraying and space spraying (adulticiding)
with permethrin derivate every 15 days. During off-duty
hours troops were authorized to wear sport and casual
clothing. Almost all soldiers spent their 15-days UN
leave at beach resorts in the Dominican Republic. The
main malaria vector in both Haiti and the Dominican
Republic is An. albimanus [28, 29]. Serum samples
were collected before and after returning from Haiti
and kept at −20 °C until processing.
Colombia
In Colombia, the highest reported altitude for Anopheles
species is 2000 m above the sea level (m.a.s.l.) [30]. For
this study, we included 26 participants (Colombia popu-
lation 1), aged 18 to 21 years, living in a malaria free
area located at 2300 m.a.s.l. in Pamplona City, but trav-
eling for at least 30 days to endemic areas in the Carib-
bean Coast of Colombia (States of Guajira, Cordoba,
Sucre, Magdalena and Santander), where the main mal-
aria vectors are An. albimanus, An. darlingi, and An.
punctimacula [31]. These participants were included in
a follow-up study to test reactivity to vector salivary pro-
teins before and after traveling to endemic areas. Partici-
pants were bled before and within a week after returning
to Pamplona.
A second group from Colombia (Colombia population
2) was formed by febrile participants (n = 42) seeking
malaria diagnosis and medical services at the Local Hos-
pital of Los Patios and Ocana in the Norte de Santander
department, which is a known low malaria endemic area,
and at the San Francisco de Asis Hospital in Quibdo in
the Choco department, considered the second highest
endemic area for malaria in the country. Serum samples
were collected and kept at −20 °C until processing.
United States
We selected 42 North Carolina Parks and Forestry rangers
participating in a randomized controlled trial to test the
efficacy of long-lasting permethrin-impregnated (LLPI)
clothing. Serum samples were collected on time 1 (before
implementation of protective clothing) and time 2 (after
implementation of protective clothing) from participants
of the control group (n = 24) and the test group (n = 18).
Aliquots of the samples were kept at −20 °C until testing.
Malaria testing by PCR
Total DNA was isolated from human samples using the
gDNA Blood Kit (Life technologies, Carlsbad, CA, USA)
according to manufacturer’s instructions. Plasmodium-
specific PCR was performed using a multiplex PCR for
the small sub-unit (SSU) rRNA gene described elsewhere
[32]. DNA from in vitro culture of the Haiti I/CDC
strain of P. falciparum and a blood sample from a thick-
smear P. vivax positive patient were used as positive
controls.
Antibody detection by ELISA
The ELISA conditions followed in this study were pub-
lished elsewhere [26]. Briefly, 96-well ELISA plates were
coated with 100 μL/well of 0.5 μg/ml of gSG6-P1 in
coating solution (Kirkegaard & Perry Laboratories, Inc.
Gaithersburg, MD) serum samples were incubated at
37 °C for 2 h in a 1/100 dilution. After washing, plates
were incubated with 100 μL/well of horseradish perox-
idase (HRP)-conjugated goat anti-human IgG (1:1000)
antibodies at 37 °C for 1.5 h. Later, each well received
100 μL/well of tetra-methyl-benzidine (TMB) (Gene-
Script, Piscataway, NJ) and 100 μL/well solution of 1 M
phosphoric acid to stop the reaction after 5 min incu-
bation with the TMB. Absorbance was measured at
450 nm.
Statistical analysis
Antibody concentrations were expressed as delta optical
density (ΔOD) calculated for each sample subtracting
the mean OD value of the negative control and blank
wells from the mean OD value of the duplicates for each
sample. Positive control ΔOD values from all plates were
recorded and averaged. This average was then divided by
individual plate positive control ΔOD values to obtain a
“calculation factor” for each plate. To correct for plate-
to-plate variations, we then multiplied each sample
ΔOD value by their respective plate calculation factor to
obtain normalized ΔOD’s. The difference in the antibody
concentrations between two independent groups was
tested using the Mann Whitney U test while the differ-
ence between two dependent groups was calculated
using Wilcoxon matched-pairs rank test. To determine
risk of disease by Odd Ratios (OR), we divided the
study sample into two groups with high and low IgG
anti-gSG6-P1 antibody levels. As a threshold the me-
dian ΔOD of 1.3075 was used. Significant differences
were established at p values higher lower 0.05. All stat-
istical testing was performed with Prism version 6.0
(Graph Pad Software Inc.) and STATA™ version 10.1
(Stata Corporation).
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Results and discussion
Anti-gSG6-P1 IgG as biomarker of exposure to “New
World” Anopheles mosquito bites
Estimating mosquito-human contact rate in endemic
areas for vector transmitted diseases like malaria, is an
important tool to measure the risk of transmission of
such diseases. Since saliva form arthropods is injected at
the time of transmission, efforts has been directed into
discover the salivary proteins able to elicit an immune
response that correspond to the level of bites a person
has received in a determined period of time. Recently,
the protein gSG6 form An. gambiae, has been reported
as a useful marker for the degree of exposure to mos-
quito bites in malaria endemic areas of Africa. Research
shows that the gSG6 protein presents little sequence
variation within species of the An. gambiae complex
(i.e. An. melas, An. quadriannulatu, An. arabiensis).
However, sequence comparison of the gSG6 with more
distant related species like An. stephensi (Asia) and An.
freeborni (America) shows a 67 to 71 % sequence iden-
tity [17]. There is not available information on the
sequence similarity between gSG6 and the South or
Central American Anopheles species An. albimanus,
An. darlingi or An. nuneztovari). Nevertheless, salivary
transcriptome analysis of the Nyssorhynchus subgenus
did not reveal SG6 presence in the salivary content of
these species [33, 34]. These reports suggested that a
possible reason for this divergence is an independent
evolutionary event of the gSG6 protein among anophel-
ine subgenera although they also state that more data
was necessary to confirm that hypothesis. In spite of
the few available information on the American species
homology with gSG6 protein [17, 35], several reports
showed the gSG6 protein to be specific to the genus
Anopheles. Consequently, we wanted to evaluate whether
participants exposed to bites of American endemic
Anopheles species develop antibodies specific to gSG6-P1,
a salivary antigen validated as a biomarker of exposure to
An. gambiae s. l. and An. funestus (main malaria vectors
in Africa) bites. To do this, we used the gSG6-P1 peptide
to assess exposure to Anopheles bites in healthy partici-
pants from Colombia living in a malaria-free area before
and after travel to endemic malaria regions (Fig. 1a). In
this group, we noticed a significant increase of individual
levels of anti-gSG6-P1 IgG after traveling (AT) to mal-
aria areas in comparison to those before traveling (BT)
(P = 0.006). A similar increase in specific gSG6-P1 IgG
levels was observed in Chilean soldiers after a 6-months
stay in malaria endemic areas in Haiti and the Dominican
Republic (P < 0.0001; Fig. 1b). These results suggest that
IgG response to gSG6-P1 is closely associated with the
degree of exposure to the bites of An. albimanus, An. dar-
lingi or An. punctimacula, the malaria vectors described
in these endemic areas in Latin America.
These results implicate that gSG6-P1 peptide, although
based on the Old World An. gambiae s. s. mosquito, can
be used to evaluate the level of exposure to bites of New
World (Americas) species of Anopheles malaria vectors.
Previous studies conducted in Senegal, Angola, and
Benin have described a correlation between the level of
gSG6-P1 IgG antibodies and the intensity of human
exposure to Anopheles bites [21, 22, 26]. Cross-response
to gSG6-P1 peptide bases on the fact that gSG6 is a well
conserved polypeptide presenting homologues in both
the Old and New World Anopheles species [36]. In
conclusion, gSG6 polypeptide as well as its gSG6-P1
peptide is suitable as a “bite” biomarker of Old World as
well as New World species of Anopheles malaria vectors.
IgG specific to gSG6-P1 as a proxy of malaria transmission
risk
Anti-gSG6-P1 IgG levels were assessed in malaria nega-
tive (−) and malaria positive (+) groups of participants
residing in malaria endemic areas of Colombia where
An. albimanus, An. darlingi, and An. punctimacula are
the main vectors. Our results demonstrated that the me-
dian level of specific IgG antibodies against gSG6-P1
was significantly higher in the malaria infected group
compared to the uninfected group (P = 0.0132) (Fig. 2a).
Serum samples in Colombia were collected in two differ-
ent states: 1) Choco with an annual parasitic incidence
(API) of 49 cases/1000 habitants, which in 2010 was
classified as a high malaria transmission region [37] and
2) Norte de Santander, which is classified as low trans-
mission area (API: 1.3 cases/1000). Interestingly, the
difference in median anti-gSG6-P1 IgG levels between
malaria infected and uninfected participants was only
significant in participants living in areas of low malaria
endemicity (P = 0.0002). In the high transmission area,
no significant difference in anti-gSG6-P1 levels was
observed (P = 0.1113) (Fig. 2b).
We also tested the hypothesis that IgG-gSG6-P1 anti-
body concentration serves as a proxy for the risk of
acquiring malaria. For that, we divided our study sub-
jects into two categories: “low antibody levels” (with a
ΔOD value <0.774) and “high antibody levels” (with a
ΔOD value ≥0.775). Participants with “high” levels of
IgG anti-gSG6-P1 antibodies had a 20.24 times higher
risk for acquiring malaria (P = 0.0001) than people with
lower levels of those antibodies (Fig. 3) suggesting that
more mosquito bites elicit higher anti-gSG6-P1 anti-
bodies and that higher antibody levels are also associated
with a higher possibility of being exposed to a bite from
an Plasmodium-infected mosquito. This suggests that
the level of gSG6-P1 specific IgG could be used as bio-
marker for the risk of malaria infection. Our data con-
firm previous studies conducted in different parts of the
Old World, in particular a recent study in a low to
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moderate malaria transmission area of Senegal, which
reported an association between IgG response to gSG6-
P1 and the status P. falciparum infection of children,
even during the dry season [22]. Furthermore, this study
showed different levels of anti-gSG6- IgG P1 antibodies
in asymptomatic Plasmodium carriers compared to clin-
ical malaria cases. In Kenya, an association between the
prevalence of P. falciparum and the levels of anti-gSG6-
P1 IgG was also described [38]. Another study in
Burkina-Faso revealed a positive correlation between
malaria incidence and IgG response against the gSG6
recombinant protein [39]. All together, the anti-salivary
gSG6-P1 peptide IgG response, previously demonstrated
to be a biomarker of exposure to Anopheles bites in
numerous contexts and in this study, could also be a
useful indicator of malaria exposure and infection. This
could also be useful to estimate the malaria risk for non-
indigenous populations taking chemoprophylaxis such as
the Chilean soldiers of our study, which helps to adapt
protection strategies for these populations. In a high
transmission situation in Colombia, we found no signifi-
cant differences in anti-gSG6-P1 levels of malaria (+)
Fig. 1 IgG antibody levels against gSG6-P1 before (BT) and after traveling (AT) to a malaria endemic area. a Healthy civilian form Colombia living
in a malaria-free area, traveling to malaria endemic places during vacation. b Military personnel from Chile deployed in Haiti in humanitarian
mission. p value denote significance by the Wilcoxon matched-pairs signed rank test
Fig. 2 IgG anti-gSG6-P1 antibody levels according to malaria status in Colombian participants. The results are presented by malaria status determine
by PCR as malaria positive (+) or negative (−) (a), and by malaria endemicity classified as “low” or “high” endemic area (b). p value denote significance
by the by the Mann Whitney U test
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and malaria (−) groups suggesting that the biomarker
might have limitation in this setting. Although the
sample size of this study group was small, it suggested
that in hyperendemic malaria areas, residents might be
highly exposed to infectious and none-infectious bites.
They thus present high levels of anti-gSG6-P1 anti-
bodies, which do not necessarily reflect the risk of mal-
aria transmission. Therefore, for such situations there is
a need for more specific biomarkers.
It is important to clarify that these findings are applic-
able for malaria transmission settings in the absence of
antimalarial drugs as prophylactic treatments. In such
cases, individuals will be still exposed to vector bites
with a reduced risk of presenting symptoms and evalu-
ation of the gSG6 antibody levels will be suitable marker
for human-vector contact.
In the African settings where previous studies with
gSG6-P1 took place, entomological records were made
to evaluate the abundance of Anopheles species present
in these areas. So, it was known that the majority of the
Anopheles species present in these areas were potential
vectors of malaria. In Colombia, between 70 and 90 % of
the mosquitoes captured during entomological surveil-
lance belong to genus An. albimanus, An. darlingi or
An. nuneztovari considered the main vectors of malaria
in the country [40, 41] while An. albimanus is the
most abundant Anopheline specie in the Hispaniola
Island [42, 43]. However, If same studies will be under-
taken in area where only half of the Anopheles are
malaria vectors, we might observe the same non sig-
nificance between infected and non-infected individ-
uals, as in hyperendemic transmission area, probably
because people would receive as many uninfected that
infected bites and no association between the level of
IgG to gSG6-P1 peptide and the risk of transmission
would be observed.
Human IgG response to gSG6-P1 for evaluating effectiveness
of individual protection against mosquito bites
A major application for an immunologically based
vector-human contact biomarker is the assessment of
the efficacy of vector control methods. For instance,
Drame et al. proved that the use of insecticide-treated
bednets and spray bombs drastically reduced the IgG
levels specific to gSG6-P1 peptide, independently of age
or transmission season [22, 27]. Other studies also sug-
gest that the IgG response against gSG6-P1 is a reliable
alternative to accurately assess the effectiveness of mal-
aria control methods and surveillance programs in areas
of low malaria risk [44, 45]. In this study, we evaluated
and compared the IgG-gSG6-P1 levels of US park
rangers using LLPI clothing during working hours and
control participants wearing untreated clothes before
and after the implementation of the strategy. At baseline,
both groups presented similar levels of IgG specific to
gSG6-P1 peptide. One year after the implementation of
LLPI clothing, we observed a significant decrease in the
concentration of IgG-gSG6-P1 antibodies in the treat-
ment group (P = 0.0049), whereas no changes were ob-
served in the controls (Fig. 4).
Anopheles punctipennis is the most abundant Anopheles
species in North Carolina (US), mostly biting outdoors
after dusk. However, it will attack humans also during day-
time in dense woodlands or close to their daylight resting
places, where the park rangers might be performing their
work activities. Monitoring the efficacy of individual use
of anti-malaria vector tools is very challenging. Previous
data suggested that the gSG6-P1 salivary biomarker can
Fig. 3 Risk evaluation of malaria using IgG antibody levels against gSG6-P1 peptide. Fisher Exact Test p = 0.0001
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be used to assess and monitor the effectiveness of individ-
ual or collective protection tools/strategies against Anoph-
eles mosquito bites [22, 26, 27]. Our study confirmed this
by showing that the level of Anopheles bites was signifi-
cantly reduced in those rangers wearing LLPI clothes. We
therefore believe that gSG6-P1 salivary biomarker is a use-
ful marker to assess and monitor the effectiveness of pro-
tection measures also against New World Anopheles bites.
This raises the importance of personal protection to
vector bites in the control of malaria. This is in accord-
ance with previous data showing significant reduction of
specific IgG levels, human-Anopheles contact and bites in
association with the use of spray bombs [26]. However all
personal protection tools do not seem to reduce the level
of mosquito bites as pointed by the same authors who
described a none-significant effect of the use of mosquito
coils or electric fans/air conditioning. In addition, by com-
paring the efficacy of individual protection tools such as
spray bombs and mosquito coils to bed-nets, the same
authors indicate that the decreases in Anopheles aggres-
siveness has essentially been due to the use of bed-nets,
meaning that these individual protection tools can be
complementary but cannot replace bed-nets in the fight
against malaria.
In the case of the Chilean troops in Haiti, air condi-
tioning facilities and bednets were used for all the troops
at base. Additionally, they use of military uniforms, left
neck and wrists exposed so although most of the body is
protected these areas can still reached by mosquitoes
during the night work. These observations suggest that
the use of these uniforms, reinforced by chloroquine
treatment, reduced the risk of presenting malaria in the
presence of higher mosquito bite exposure (There has
been only one case of malaria in 10 years of mission in
Haiti), and that gSG6-P1 is a useful marker to show that
in the event of increased exposure to mosquito bites
subjects were protected against infection.
Conclusion
The synthetic peptide gSG6-P1 is useful as a proxy indica-
tor of human-vector contact with American Anopheles
species. Further investigation is needed to compare the
immune response against the specific mosquito species
vectors of malaria in America with the response elicited
against gSG6-P1 in areas with different malaria endemicity.
It is also a useful tool for the evaluation vector control
interventions and devices designed to decrease mosquito
bite and disease transmission in human populations.
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